Two Decades of Neurosurgical Device Innovation: A Comprehensive Analysis of FDA Authorization Trends From 7800 Approvals by Subspecialty, Regulatory Pathway, and Approval Time

BACKGROUND AND OBJECTIVES: Technological progress has accelerated neurosurgical care, yet a panoramic view of these innovations remains lacking. This study aims to analyze all US Food and Drug Administration (FDA) authorizations issued from 2000 to 2023 to map neurosurgical device output by subspecialty, compare regulatory pathways and approval times, and identify factors affecting market entry. METHODS: All devices cleared or approved by the FDA Neurology and Orthopedic Review Panels (January 2000-December 2023) were extracted from publicly available 510(k), De Novo, Humanitarian Device Exemption, and Premarket Approval databases. Devices were assigned to 1 of 9 neurosurgical subspecialties and stratified by regulatory pathway, device class, company maturity, and geographic origin. Descriptive statistics, analysis of variance, and Welch t-tests assessed temporal and categorical differences. RESULTS: Of 16 064 devices reviewed by the FDA Neurology and Orthopedic panels, 7873 (49.0%) were neurosurgical, rising 172.1% over the period. Spine and peripheral nerve (5227 devices) and stereotactic and functional (1378) dominated volume and number of new market entries, while cerebrospinal fluid disorders (n = 149) and cranial trauma (n = 111) had fewer approvals. Cerebrovascular and endovascular (95.5%) and cranial trauma (200.0%) showed the largest growth rates, while cerebrospinal fluid disorders (-54.2%) and general cranial surgery (-34.5%) declined over time. Mean approval time varied by subspecialty (P < .001), the shortest for spine and peripheral nerve (119.0 ± 102.7 days) and the longest for stereotactic and functional (158.7 ± 121.5 days). Approval or clearance times were strongly influenced by regulatory pathway and device class (both P < .001), with Premarket Approval devices (584.8 ± 323.3 days) the longest. Mature companies achieved faster approvals compared with startups (114.9 ± 97.0 vs 174.5 ± 133.9 days, P < .001). CONCLUSION: Neurosurgical device output has more than doubled, but volume concentrates where predicates are rich and reimbursement established, not where clinical need or novelty is the greatest. Pathway architecture, device complexity, and sponsor experience influence approval efficiency more than novelty.